Compare JYNT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | ADAG |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | China |
| Employees | N/A | 138 |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 146.3M |
| IPO Year | 2014 | 2020 |
| Metric | JYNT | ADAG |
|---|---|---|
| Price | $8.92 | $2.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $8.00 |
| AVG Volume (30 Days) | 44.3K | ★ 108.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $117,696,356.00 | N/A |
| Revenue This Year | $5.65 | $3,688.61 |
| Revenue Next Year | $3.86 | $17.39 |
| P/E Ratio | $76.42 | ★ N/A |
| Revenue Growth | ★ 15.49 | N/A |
| 52 Week Low | $7.50 | $1.33 |
| 52 Week High | $13.47 | $3.53 |
| Indicator | JYNT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 54.77 |
| Support Level | $8.25 | $1.64 |
| Resistance Level | $10.47 | $3.19 |
| Average True Range (ATR) | 0.40 | 0.30 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 44.80 | 48.01 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.